Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

8,527 total articles

Newmont: Buy the Dip — Tactical Swing Into a High-Quality Gold Producer

Newmont: Buy the Dip — Tactical Swing Into a High-Quality Gold Producer

Newmont (NEM) pulled back sharply in June as gold prices slid and production guidance was trimmed. The market overreacted to a temporary hit to margins — Newmont's balance sheet strength, $9.24B in trailing free cash flow and an enlarged buyback provide a clear buy-the-dip setup. We recommend a tactical long with an explicit entry at $94.00, stop a…

Palantir’s Ontology Advantage: Buy the Pullback, Not the Hype

Palantir’s Ontology Advantage: Buy the Pullback, Not the Hype

Palantir (PLTR) has been swept up in a broad SaaS de-risking that knocked the stock nearly 40% off its 2025 peak. The fundamentals tell a different story: very high growth, strong profitability and cash generation, and an enterprise-grade ontology layer that’s hard to replicate. This trade idea outlines a long entry after the sell-off, with a measu…

A Contrarian Play on Whirlpool: Buying the Panic in an Appliance Cyclical

A Contrarian Play on Whirlpool: Buying the Panic in an Appliance Cyclical

Whirlpool is trading like the housing market will never recover: deeply discounted relative to recent history, weak margins, suspended dividend and legal probes. That said, the balance sheet and valuation suggest substantial upside if housing stabilizes and inventory normalization continues. This trade idea lays out a specific long entry, stop, tar…

Forte Biosciences: FB-102 Is Graduating Into a Platform Narrative — Trade the Re-rate, Defend With Stops

Forte Biosciences: FB-102 Is Graduating Into a Platform Narrative — Trade the Re-rate, Defend With Stops

Forte Biosciences is trading like a breakout biotech. Technical momentum and increasing short interest have produced a quick re-rate; the investment case now hinges on FB-102 being positioned as a platform that can drive multiple clinical programs. This trade idea recommends a tactical long with a clearly defined stop and target, while outlining th…

Buying Porsche ADRs Here: A Patient Long With Asymmetric Upside

Buying Porsche ADRs Here: A Patient Long With Asymmetric Upside

Porsche Automobil Holding SE's ADR (POAHY) is trading near its 52-week low on thin OTC liquidity but at compelling accounting multiples: market cap ~$9.35B, P/E ~3.2, and P/B ~0.21. With a modest dividend, a near-term payable date, depressed technicals (RSI ~33) and elevated short activity, the name presents an asymmetric risk/reward for patient lo…

Credo (CRDO): Buy the AI Connectivity Story on Post-Rally Consolidation

Credo (CRDO): Buy the AI Connectivity Story on Post-Rally Consolidation

Credo Technology is converting raw AI bandwidth demand into outsized revenue growth through SerDes chiplets and optical connectivity. Recent results and insider conviction support further upside, but the stock carries a high valuation and concentrated customer exposure. This trade idea proposes a mid-term long with a disciplined stop below the 50-d…

Medtronic: Guidance Set Low — Buy the Dip, Ride the Recovery

Medtronic: Guidance Set Low — Buy the Dip, Ride the Recovery

Medtronic looks set to beat conservative guidance over the coming quarters. The shares trade at a reasonable PE (~22) with a $105B market cap, a 3.5% yield, and healthy free cash flow. Technicals are constructive and recent M&A and product tailwinds create multiple catalysts. This is a buy for a swing trade into a re-acceleration in growth, with cl…